REFERENCES
1. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol 2016;70:93-105.
2. Feng X, Zhang L, Tu W, Cang S. Frequency, incidence and survival outcomes of clear cell renal cell carcinoma in the United States from 1973 to 2014: a SEER-based analysis. Medicine (Baltimore) 2019;98:e16684.
3. Schiavoni V, Campagna R, Pozzi V, et al. Recent advances in the management of clear cell renal cell carcinoma: novel biomarkers and targeted therapies. Cancers (Basel) 2023;15:3207.
4. Kim SH, Park B, Hwang EC, et al. Retrospective multicenter long-term follow-up analysis of prognostic risk factors for recurrence-free, metastasis-free, cancer-specific, and overall survival after curative nephrectomy in non-metastatic renal cell carcinoma. Front Oncol 2019;9:859.
5. Wang C, Xu H, Liao X, et al. Hypertension promotes the proliferation and migration of ccRCC cells by downregulation of TIMP3 in tumor endothelial cells through the miR-21-5p/TGFBR2/P38/EGR1 Axis. Mol Cancer Res 2023;21:62-75.
6. Hammer A, Yang G, Friedrich J, et al. Role of the receptor Mas in macrophage-mediated inflammation in vivo. Proc Natl Acad Sci U S A 2016;113:14109-14.
7. Temme S, Yakoub M, Bouvain P, et al. Beyond vessel diameters: non-invasive monitoring of flow patterns and immune cell recruitment in murine abdominal aortic disorders by multiparametric MRI. Front Cardiovasc Med 2021;8:750251.
8. Yang G, Chu PL, Rump LC, Le TH, Stegbauer J. ACE2 and the homolog collectrin in the modulation of nitric oxide and oxidative stress in blood pressure homeostasis and vascular injury. Antioxid Redox Signal 2017;26:645-59.
9. Yang G, Istas G, Höges S, et al. Angiotensin-(1-7)-induced Mas receptor activation attenuates atherosclerosis through a nitric oxide-dependent mechanism in apolipoproteinE-KO mice. Pflugers Arch 2018;470:661-7.
10. Tan WSD, Liao W, Zhou S, Mei D, Wong WF. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases. Curr Opin Pharmacol 2018;40:9-17.
11. Perlot T, Penninger JM. ACE2 - from the renin-angiotensin system to gut microbiota and malnutrition. Microbes Infect 2013;15:866-73.
12. Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG, Widdop RE. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond) 2011;121:297-303.
13. Matysiak-Burzyńska ZE, Nowakowska M, Domińska K, Kowalska K, Płuciennik E, Piastowska-Ciesielska AW. Silencing of angiotensin receptor 1 interferes with angiotensin II oncogenic activity in endometrial cancer. J Cell Biochem 2018;119:9110-21.
14. Daugherty A, Manning MW, Cassis LA. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 2001;134:865-70.
15. O'Connor AT, Haspula D, Alanazi AZ, Clark MA. Roles of angiotensin III in the brain and periphery. Peptides 2022;153:170802.
16. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000;275:33238-43.
17. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87:E1-9.
18. Nakagawasai O, Takahashi K, Koyama T, Yamagata R, Nemoto W, Tan-No K. Activation of angiotensin-converting enzyme 2 produces an antidepressant-like effect via MAS receptors in mice. Mol Brain 2023;16:52.
19. Qaradakhi T, Gadanec LK, McSweeney KR, et al. The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases. Clin Exp Pharmacol Physiol 2020;47:751-8.
20. Rushworth CA, Guy JL, Turner AJ. Residues affecting the chloride regulation and substrate selectivity of the angiotensin-converting enzymes (ACE and ACE2) identified by site-directed mutagenesis. FEBS J 2008;275:6033-42.
21. Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/Angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on Angiotensin-(1-7). Physiol Rev 2018;98:505-53.
22. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol 2013;216:R1-R17.
23. Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol 2016;310:H137-52.
24. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003;100:8258-63.
25. Hassani B, Attar Z, Firouzabadi N. The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies. Cancer Cell Int 2023;23:254.
26. O'Rawe M, Kilmister EJ, Mantamadiotis T, Kaye AH, Tan ST, Wickremesekera AC. The renin-angiotensin system in the tumor microenvironment of glioblastoma. Cancers (Basel) 2021;13:4004.
27. Perini MV, Dmello RS, Nero TL, Chand AL. Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments. Pharmacol Ther 2020;211:107527.
28. Imai N, Hashimoto T, Kihara M, et al. Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest 2007;87:189-98.
29. Nguyen L, Ager EI, Neo J, Christophi C. Regulation of colorectal cancer cell epithelial to mesenchymal transition by the renin angiotensin system. J Gastroenterol Hepatol 2016;31:1773-82.
30. Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med 2019;18:121-6.
32. Liu Y, Li B, Wang X, et al. Angiotensin-(1-7) suppresses hepatocellular carcinoma growth and angiogenesis via complex interactions of angiotensin II Type 1 Receptor, angiotensin II type 2 receptor and Mas receptor. Mol Med 2015;21:626-36.
33. Murphy KT, Hossain MI, Swiderski K, et al. Mas receptor activation slows tumor growth and attenuates muscle wasting in cancer. Cancer Res 2019;79:706-19.
34. Larrinaga G, Pérez I, Sanz B, et al. Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. Regul Pept 2010;165:218-23.
35. Errarte P, Beitia M, Perez I, et al. Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients. PLoS One 2017;12:e0181711.
36. Bai S, Wu Y, Yan Y, et al. Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma. Sci Rep 2020;10:13659.
37. Rehman A, Fatima I, Wang Y, et al. Unveiling the multi-target compounds of Rhazya stricta: discovery and inhibition of novel target genes for the treatment of clear cell renal cell carcinoma. Comput Biol Med 2023;165:107424.
38. Kim K, Ko Y, Ko DS, Kim YH. Prognostic significance of COVID-19 receptor ACE2 and recommendation for antihypertensive drug in renal cell carcinoma. Biomed Res Int 2020;2020:2054376.
39. Khanna P, Soh HJ, Chen CH, et al. ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. Sci Transl Med 2021;13:eabc0170.
40. Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science 2017;357:eaan2507.
41. Javorhazy A, Farkas N, Beothe T, Pusztai C, Szanto A, Kovacs G. Lack of TMEM27 expression is associated with postoperative progression of clinically localized conventional renal cell carcinoma. J Cancer Res Clin Oncol 2016;142:1947-53.
42. Grewal R, Choung HYG, Roberts LL, et al. TMEM27 expression and clinical characteristics and survival in clear cell renal cell carcinoma. Acta Oncol 2022;61:1507-11.
43. Dolley-Hitze T, Jouan F, Martin B, et al. Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer 2010;103:1698-705.
44. Verhoest G, Dolley-Hitze T, Jouan F, et al. Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma. Biomed Res Int 2014;2014:901371.
45. Zheng S, Yang Y, Song R, et al. Ang-(1-7) promotes the migration and invasion of human renal cell carcinoma cells via Mas-mediated AKT signaling pathway. Biochem Biophys Res Commun 2015;460:333-40.
46. Sobczuk P, Trzcinska-Danielewicz J, Koperski L, Girstun A, Cudnoch-Jedrzejewska A. Angiotensin-(1-7) can promote cell migration and tumor growth of clear cell renal cell carcinoma. J Physiol Pharmacol 2022:73.
47. Yang Y, Liang J, Zhao C, et al. NHERF4 hijacks Mas-mediated PLC/AKT signaling to suppress the invasive potential of clear cell renal cell carcinoma cells. Cancer Lett 2021;519:130-40.
48. Larrinaga G, Valdivia A, Arrieta-Aguirre I, et al. The expression of Alamandine receptor MrgD in clear cell renal cell carcinoma is associated with a worse prognosis and unfavorable response to antiangiogenic therapy. Int J Mol Sci 2024;25:1499.
49. Cui H, Xu L, Li Z, et al. Integrated bioinformatics analysis for the identification of potential key genes affecting the pathogenesis of clear cell renal cell carcinoma. Oncol Lett 2020;20:1573-84.
50. Solano-Iturri JD, Echevarría E, Unda M, et al. Clinical implications of (Pro)renin receptor (PRR) expression in renal tumours. Diagnostics (Basel) 2021;11:272.
51. Yoon HE, Kim EN, Kim MY, et al. Age-associated changes in the vascular renin-angiotensin system in mice. Oxid Med Cell Longev 2016;2016:6731093.
52. Costa-Fraga FP, Goncalves GK, Souza-Neto FP, et al. Age-related changes in vascular responses to angiotensin-(1-7) in female mice. J Renin Angiotensin Aldosterone Syst 2018;19:1470320318789332.
53. Chauhan VP, Martin JD, Liu H, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 2013;4:2516.
54. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A 2011;108:2909-14.
55. Rhodes DR, Ateeq B, Cao Q, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A 2009;106:10284-9.
56. Alhusban A, Al-Azayzih A, Goc A, Gao F, Fagan SC, Somanath PR. Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis. J Pharmacol Exp Ther 2014;350:635-45.
57. Ishiguro H, Ishiguro Y, Kubota Y, Uemura H. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 2007;67:924-32.
58. Takahashi S, Uemura H, Seeni A, et al. Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer. Prostate 2012;72:1559-72.
59. Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 2007;22:577-84.
60. Morris ZS, Saha S, Magnuson WJ, et al. Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Cancer 2016;122:2487-95.
61. Li XY, Sun JF, Hu SQ. The renin-angiotensin system blockers as adjunctive therapy for cancer: a meta-analysis of survival outcome. Eur Rev Med Pharmacol Sci 2017; 21:1375-83.
62. Sun H, Li T, Zhuang R, Cai W, Zheng Y. Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients? Medicine (Baltimore) 2017;96:e6394.
63. Datzmann T, Fuchs S, Andree D, Hohenstein B, Schmitt J, Schindler C. Systematic review and meta-analysis of randomised controlled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer. Eur J Intern Med 2019;64:1-9.
64. Shen J, Huang YM, Wang M, et al. Renin-angiotensin system blockade for the risk of cancer and death. J Renin Angiotensin Aldosterone Syst 2016;17:1470320316656679.
65. Reichhart N, Figura A, Skosyrski S, Strauß O. Control of the retinal local RAS by the RPE: an interface to systemic RAS activity. Exp Eye Res 2019;189:107838.
66. Cruz-López EO, Uijl E, Danser AHJ. Perivascular adipose tissue in vascular function: does locally synthesized angiotensinogen play a role? J Cardiovasc Pharmacol 2021;78:S53-62.
67. Cao W, Li A, Wang L, et al. A salt-induced reno-cerebral reflex activates renin-angiotensin systems and promotes CKD progression. J Am Soc Nephrol 2015;26:1619-33.
68. Liu Y, Li L, Qiu M, et al. Renal and cerebral RAS interaction contributes to diabetic kidney disease. Am J Transl Res 2019; 11:2925-39.
69. Ren L, Lu X, Danser AHJ. Revisiting the brain renin-angiotensin system-focus on novel therapies. Curr Hypertens Rep 2019;21:28.
70. Li J, Liang M, Zeng T, et al. Silencing of central (Pro)renin receptor ameliorates salt-induced renal injury in chronic kidney disease. Antioxid Redox Signal 2021;35:93-112.
71. Atkinson AJ Jr. Intracerebroventricular drug administration. Transl Clin Pharmacol 2017;25:117-24.
72. Cohen-Pfeffer JL, Gururangan S, Lester T, et al. Intracerebroventricular delivery as a safe, long-term route of drug administration. Pediatr Neurol 2017;67:23-35.
73. Chen J, Zhang D, Zhang J, Wang Y. Pathological changes in the brain after peripheral burns. Burns Trauma 2023;11:tkac061.
74. Yang G, Waheed S, Wang C, Shekh M, Li Z, Wu J. Exosomes and their bioengineering strategies in the cutaneous wound healing and related complications: current knowledge and future perspectives. Int J Biol Sci 2023;19:1430-54.
75. Wang J, Tang W, Yang M, et al. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy. Biomaterials 2021;273:120784.
76. Huang Z, Guo L, Huang L, Shi Y, Liang J, Zhao L. Baicalin-loaded macrophage-derived exosomes ameliorate ischemic brain injury via the antioxidative pathway. Mater Sci Eng C Mater Biol Appl 2021;126:112123.
77. Li F, Zhao L, Shi Y, Liang J. Edaravone-loaded macrophage-derived exosomes enhance neuroprotection in the rat permanent middle cerebral artery occlusion model of stroke. Mol Pharm 2020;17:3192-201.
78. Tao B, Du R, Zhang X, et al. Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy. J Control Release 2023;363:692-706.
79. Tian T, Zhang HX, He CP, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials 2018;150:137-49.
80. Wu T, Liu Y, Cao Y, Liu Z. Engineering macrophage exosome disguised biodegradable nanoplatform for enhanced sonodynamic therapy of glioblastoma. Adv Mater 2022;34:e2110364.
81. Jia G, Han Y, An Y, et al. NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo. Biomaterials 2018;178:302-16.
82. Li B, Chen X, Qiu W, et al. Synchronous disintegration of ferroptosis defense axis via engineered exosome-conjugated magnetic nanoparticles for glioblastoma therapy. Adv Sci (Weinh) 2022;9:e2105451.
83. Liu J, Sun Y, Zeng X, et al. Engineering and characterization of an artificial drug-carrying vesicles nanoplatform for enhanced specifically targeted therapy of glioblastoma. Adv Mater 2023;35:e2303660.
84. Wang R, Wang X, Zhao H, et al. Targeted delivery of hybrid nanovesicles for enhanced brain penetration to achieve synergistic therapy of glioma. J Control Release 2024;365:331-47.
85. Xu W, Wu Y, Liu W, et al. Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma. Int J Biol Sci 2022;18:4884-900.
86. Vallejo-Ardila DL, Fifis T, Burrell LM, Walsh K, Christophi C. Renin-angiotensin inhibitors reprogram tumor immune microenvironment: a comprehensive view of the influences on anti-tumor immunity. Oncotarget 2018;9:35500-11.
87. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155:739-52.
88. Xu K, Han H, Luo Y, Ye H, Lin H, Ni L. The angiotensin-converting enzyme inhibitory state promotes the transformation of non-small cell lung cancer blood supply pattern toward vasculogenic mimicry formation. Front Oncol 2021;11:663671.
89. Geng B, Liu W, Wang J, et al. The categorizations of vasculogenic mimicry in clear cell renal cell carcinoma unveil inherent connections with clinical and immune features. Front Pharmacol 2023;14:1333507.
90. Wang X, Yang R, Wang Q, Wang Y, Ci H, Wu S. Aberrant expression of vasculogenic mimicry, PRRX1, and CIP2A in clear cell renal cell carcinoma and its clinicopathological significance. Medicine (Baltimore) 2019;98:e17028.
91. Liu Q, Zhao E, Geng B, et al. Tumor-associated macrophage-derived exosomes transmitting miR-193a-5p promote the progression of renal cell carcinoma via TIMP2-dependent vasculogenic mimicry. Cell Death Dis 2022;13:382.
92. Yan L, Li R, Li D, Zhu Y, Lv Z, Wang B. Development of a novel vasculogenic mimicry-associated gene signature for the prognostic assessment of osteosarcoma patients. Clin Transl Oncol 2023;25:3501-18.
93. Peliky Fontes MA, Kangussu LM, Simões-e-Silva AC. Chapter 24 - the renin-angiotensin system, emotional stress and anxiety. In: Pilowsky PM, editors. Angiotensin from the kidney to coronavirus. Academic Press; 2023. p. 623-40.
94. Eckerling A, Ricon-Becker I, Sorski L, Sandbank E, Ben-Eliyahu S. Stress and cancer: mechanisms, significance and future directions. Nat Rev Cancer 2021;21:767-85.
95. Cui Y, Zhuang M, Huang Z, et al. An antihypertensive drug-AT1 inhibitor attenuated BRCA development promoted by chronic psychological stress via Ang II/PARP1/FN1 pathway. Biochim Biophys Acta Mol Basis Dis 2024;1870:167031.
96. Baffour-Awuah B, Man M, Goessler KF, et al. Effect of exercise training on the renin-angiotensin-aldosterone system: a meta-analysis. J Hum Hypertens 2024;38:89-101.
97. Kaschina E. Cross-talk between exercises and renin-angiotensin-aldosterone-system blockade in hypertension. Hypertens Res 2024;47:1981-3.
98. Wang Q, Zhou W. Roles and molecular mechanisms of physical exercise in cancer prevention and treatment. J Sport Health Sci 2021;10:201-10.
99. McTiernan A, Friedenreich CM, Katzmarzyk PT, et al. 2018 PHYSICAL ACTIVITY GUIDELINES ADVISORY COMMITTEE*. Physical activity in cancer prevention and survival: a systematic review. Med Sci Sports Exerc 2019;51:1252-61.
